According to GlaxoSmithKline's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 4.43932. At the end of 2021 the company had a P/E ratio of 14.7.
Year | P/E ratio | Change |
---|---|---|
2021 | 14.7 | 45.85% |
2020 | 10.1 | -35.71% |
2019 | 15.7 | -0.75% |
2018 | 15.8 | -55.39% |
2017 | 35.5 | -44.04% |
2016 | 63.4 | 919.49% |
2015 | 6.22 | -66.06% |
2014 | 18.3 | 54.42% |
2013 | 11.9 | 1.24% |
2012 | 11.7 | 6.27% |
2011 | 11.0 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
![]() Novartis NVS | 28.5 | 542.24% | ๐จ๐ญ Switzerland |
![]() Pfizer PFE | 7.14 | 60.86% | ๐บ๐ธ USA |
![]() Sanofi SNY | 19.0 | 329.04% | ๐ซ๐ท France |
![]() Merck MRK | 18.4 | 314.86% | ๐บ๐ธ USA |
![]() AstraZeneca AZN | 64.7 | 1,357.81% | ๐ฌ๐ง UK |
![]() Teva Pharmaceutical Industries TEVA | -4.13 | -193.08% | ๐ฎ๐ฑ Israel |
![]() Dynavax Technologies
DVAX | 4.23 | -4.83% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.